An insight into the molecular characteristics of hepatitis C virus for clinicians

Saudi Medical Journal

Volumn 37, Issue 5, 2016, Pages 483-491

  Du, Lingyao ^a   Tang, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CLAUDIN; NONSTRUCTURAL PROTEIN 5B; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR BI; TRANSFORMING GROWTH FACTOR BETA; ANTIVIRUS AGENT; UNTRANSLATED REGION; VIRAL PROTEIN;

3' UNTRANSLATED REGION; APOPTOSIS; CELL PROLIFERATION; DOWN REGULATION; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOGENICITY; INTERNAL RIBOSOME ENTRY SITE; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONHUMAN; OPEN READING FRAME; REVIEW; UPREGULATION; VIRUS ATTACHMENT; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS TRANSCRIPTION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN SYNTHESIS; UNTRANSLATED REGION; VIROLOGY; VIRUS GENOME;

ANTIVIRAL AGENTS; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; OPEN READING FRAMES; PROTEIN BIOSYNTHESIS; UNTRANSLATED REGIONS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84965146458     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: 10.15537/smj.2016.5.14178     Document Type: Review

References (65)

1. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral-hepatitis type-a or type-B. N Engl J Med 1975; 292: 767-770
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342
4. First WHO hepatitis C treatment guidelines. B World Health Organ 2014; 92: 312-313
5. Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 2006; 3: 29-34
6. Wang CY, Sarnow P, Siddiqui A. Translation of human hepatitis-C virus-Rna in cultured-cells is mediated by an internal ribosome-binding mechanism. J Virol 1993; 67: 3338-3344
7. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5’ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75: 12047-12057
8. Friebe P, Bartenschlager R. Genetic analysis of sequences in the 3 ‘ nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 2002; 76: 5326-5338
9. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A 1991; 88: 5547-5551
10. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626
11. Tang H, Grise H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond) 2009; 117: 49-65
12. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80: 5308-5320
13. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 12766-12771
14. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000; 74: 10055-10062
15. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desollibere I, Reiser I, et al. Anti-CD81 antibodies can prevent a hepatitis c virus infection in vivo. Hepatology 2008; 48: 1761-1768
16. Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007; 81: 8063-8071
17. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-805
18. Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008; 82: 3555-3560
19. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You HN, de Jong YP, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886
20. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487-5492
21. El-Hage N, Luo G. Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. J Gen Virol 2003; 84 (Pt 10): 2761-2769
22. Huang H, Sun F, Owen DM, Li WP, Chen Y, Gale M, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. P Natl Acad Sci USA 2007; 104: 5848-5853
23. Chang KS, Jiang JY, Cai ZH, Luo GX. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007; 81: 13783-13793
24. Gastaminza P, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 2006; 80: 11074-11081
25. Ma YH, Anantpadma M, Timpe JM, Shanmugam S, Singh SM, Lemon SM, et al. Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J Virol 2011; 85: 86-97
26. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61
27. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006; 290: G847-G851
28. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008; 48: 1420-1429
29. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 2004; 101: 4262-4267
30. Pekow JR, Han AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis c-related cirrhosis. Cancer 2007; 109: 2490-2496
31. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepatitis 2006; 13: 73-80
32. Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res 2008; 38: 1-26
33. Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takigawa Y, Ikeda M, Kato N, et al. NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 2006; 87 (Pt 6): 1703-1713
34. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/ waf1 gene expression in a p53-dependent manner. Journal of Virology 2001; 75: 1401-1407
35. Cho JW, Baek WK, Yang SH, Chang J, Sung YC, Suh MH. HCV core protein modulates Rb pathway through pRb downregulation and E2F-1 up-regulation. Bba-Mol Cell Res 2001; 1538: 59-66
36. Munakata T, Liang Y, Kim S, McGivern DR, Huibregtse J, Nomoto A, et al. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog 2007; 3: 1335-1347
37. Lundin M, Monne M, Widell A, von Heijne G, Persson MAA. Topology of the membrane-associated hepatitis C virus protein NS4B. Journal of Virology 2003; 77: 5428-5438
38. Park JS, Yang JM, Min MK. Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. Biochem Biophys Res Commun 2000; 267: 581-587
39. Einav S, Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, et al. The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without ha-ras co-transfection. Hepatology 2008; 47: 827-835
40. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19: 2793-2798
41. De Clercq E. Current race in the development of DAAs (directacting antivirals) against HCV. Biochem Pharmacol 2014; 89: 441-452
42. Kanda T, Yokosuka O, Omata M. Faldaprevir for the treatment of hepatitis C. Int J Mol Sci 2015; 16: 4985-4996
43. Rangnekar AS, Fontana RJ. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 2012; 36: 104-114
44. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236
45. Chae HB. [New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent]. Korean J Gastroenterol 2015; 66: 5-9
46. Kiser JJ, Burton JR, Jr., Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 596-606
47. Gritsenko D, Hughes G. Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T 2015; 40: 256-276
48. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 2015; 59: 979-987
49. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 2015; 59: 988-997
50. Hughes M, Griffin S, Harris M. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 2009; 90: 1329-1334
51. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100
52. Garimella T, Wang R, Luo WL, Wastall P, Kandoussi H, DeMicco M, et al. Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine/ naloxone. Antimicrob Agents Chemother 2015; 59: 5503-5510
53. Hill L. Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. Top Antivir Med 2015; 23: 92-96
54. Garimella T, Wang R, Luo W, Hwang C, Sherman D, Kandoussi H, et al. The effect of renal impairment on single-dose pharmacokinetics of daclatasvir, an HCV NS5A inhibitor. J Viral Hepatitis 2014; 21: 32
55. Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, et al. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther 2015; 20: 535-543
56. Kwon HJ, Xing W, Chan K, Niedziela-Majka A, Brendza KM, Kirschberg T, et al. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. PLoS One 2015; 10: e0122844
57. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
58. Kayali Z, Schmidt WN. Finally sofosbuvir: an oral anti-HCV drug with wide performance capability. Pharmgenomics Pers Med 2014; 7: 387-998
59. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221
60. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493
61. Dvory-Sobol H, Voitenleitner C, Mabery E, Skurnac T, Lawitz EJ, McHutchison J, et al. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2014; 58: 6599-6606
62. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993; 67: 3923-3930
63. Zibert A, Dudziak P, Schreier E, Roggendorf M. Characterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1-specific antibodies in viral neutralization. Arch Virol 1997; 142: 523-534
64. El-Attar LMR, Partidos CD, Howard CR. A Peptide mimotope of hepatitis c virus e2 protein is immunogenic in mice and block human anti-HCV sera. J Med Virol 2010; 82: 1655-1665
65. Triyatni M, Berger EA, Saunier B. A new model to produce infectious hepatitis C virus without the replication requirement. PLoS Pathog 2011; 7: e1001333.